Medtronic received information via literature regarding the long-term outcomes in patients with degenerated mitral bioprosthetic valves who were treated with transcatheter valve-in-valve implantation using the melody valve.All data were retrospectively collected from a single center between july 2011 and october 2013.The study population included 13 patients and was predominantly female with a mean age of 75 years.Of those, 3 were previously implanted with medtronic surgical valves in the mitral position: hancock (1) and mosaic (2).All patients underwent valve-in-valve implantation with a 22 mm medtronic melody transcatheter valve.No serial number were provided.Among all patients, 6 deaths occurred during follow-up.The reported causes of death were: septic shock and pneumonia (1), lymphoma (1), possible sudden cardiac death (1), and unknown causes (3).Based on the available information, medtronic product was not directly associated with the deaths.For the hancock patient (patient 3), adverse events included: mitral regurgitation that required valve-in-valve implantation 10 years after the hancock valve was implanted.Based on the available information, medtronic product was directly associated with the adverse event.For the mosaic patients, adverse events included: mitral regurgitation that required valve-in-valve implantation 4 years after the mosaic valve was implanted (patient 9), and mitral stenosis that required valve-in-valve implantation 8 years after the mosaic valve was implanted (patient 12).Based on the available information, medtronic product was directly associated with the adverse events.Adverse events observed after melody valve-in-valve implantation: severe mitral regurgitation caused by a loss of leaflet coaptation that required a repeat transcatheter valve-in-valve procedure (4.4 years after initial valve-in-valve), right iliac artery dissection with retroperitoneal bleeding that required surgical repair, thigh hematoma that required endovascular therapy, hemothorax that required chest tube drainage and blood transfusion, arterio-venous fistula, mild-moderate-severe mitral regurgitation, trace paravalvular leak, and increased mean transvalvular gradients.Based on the available information, medtronic product was directly associated with the adverse events.No additional adverse patient effects or product performance issues were reported.
|